Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19498174 | 0.79 | PDPK1 (0.34) | PDPK1ALDH1A1PIK3CDPIK3CA | |
| SCHEMBL15958444 | 0.74 | PIK3CA (0.31) | PIK3CA | |
| SCHEMBL17624116 | 0.70 | CHRM3 (0.35) | CHRM3ALDH1A1 | |
| SCHEMBL17623865 | 0.69 | CHRM3 (0.37) | CHRM3 | |
| SCHEMBL322784 | 0.69 | CHRM3 (0.45) | PDPK1CHRM3ALDH1A1 | |
| SCHEMBL17624438 | 0.68 | HTR2A (0.41) | ALDH1A1 | |
| SCHEMBL18756130 | 0.67 | CHRM3 (0.49) | PDPK1CHRM3ALDH1A1 | |
| SCHEMBL6764925 | 0.66 | CHRM3 (0.41) | PDPK1CHRM3ALDH1A1 | |
| SCHEMBL321867 | 0.65 | PIK3CD (0.60) | PIK3CDPIK3CA | |
| SCHEMBL19563045 | 0.63 | HTT (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-26 | — | — | US | disclosed |
| WO-2016044604-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, ADRM1, PRMT1 | PDPK1 1629/4885CHRM3 2332/4885ALDH1A1 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.